Table 2.

SLE patient preferences and perceptions regarding aggressive treatment

	African-American	White	P-valuea
Willing to receive CYC, n (%)b	63 (67.0)	45 (84.9)	0.02
Familiarity, mean (s.d.)	0.36 (0.67)	0.57 (0.82)	0.10
Perception of effectiveness, mean (s.d.)	20.67 (4.37)	21.25 (4.27)	0.44
Perception of risk, mean (s.d.)	11.14 (2.11)	11.11 (2.33)	0.95
Willing to participate in a clinical trial involving a new medication, n (%)c	79 (68.7)	46 (80.7)	0.10

^aSignificance level of the χ² statistic for categorical variables and two-tailed t-test (or Wilcoxon’s rank sum test) for continuous variables. ^bAmong patients who had never received CYC (n = 147, 94 African-American and 53 white). ^cAmong patients who had never participated in a clinical trial involving a new medication (n = 172, 115 African-American and 57 white).